A Biomarker-BasedPlatform for Early Diagnosis of Chronic Liver Disease to EnablePersonalized Therapy

Project Details

Description

Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, type2 diabetes, and increased alcohol intake, which are all on the rise. It is predicted that healthy life expectancy will decrease in Europe over the next 30 years because of deaths
due to liver disease. Liver cirrhosis develops after a very long period of asymptomatic liver fibrosis, staying undetected until patients develop severe complications due to cirrhosis or liver cancer. Currently the only effective treatment available is liver transplantation which is not applicable to all patients. If fibrosis is detected early, to target the course of liver disease, then liver fibrosis is reversible.
The LIVERAIM project concentrates a team of renowned clinical centres and Industrial partners, including SMEs, with great expertise in the field of Liver Disease, the aim being to design and validate a screening platform with biomarkers for population screening to use across Europe. The objective is to identify liver disease early and apply personalized therapeutic interventions. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using biobank plasma samples from 40,000 subjects from previous H2020 EUfunded cohorts. LIVERAIM will develop a screening platform with biomarkers using AI for personalized early diagnosis of fibrosis to be validated in a RCT of 100K subjects from 6 representative EU countries. The platform will be linked to tailored, personalized therapeutic interventions to halt fibrosis progression. With LIVERAIM, early diagnosis and personalized intervention can stop liver disease progression, help decrease morbidity and mortality and the associated societal burdens both economic and health inequity.
AcronymLIVERAIM
StatusActive
Effective start/end date1/03/2428/02/30

Collaborative partners

  • Universitat Autònoma de Barcelona (UAB)
  • Clinical Pharmacology Unit (lead)
  • Region of Southern Denmark
  • Johannes Gutenberg University of Mainz
  • University of Padova
  • Institute of Cardiometabolism and Nutrition IHU ICAN
  • Università degli Studi di Torino
  • Barcelona Institute for Global Health (ISGlobal)
  • Universitat de Barcelona (UB)
  • Roche Diagnostics International L.T.D.
  • Siemens Healthcare
  • NORDIC BIOSCIENCE A
  • Sysmex Europe SE
  • ASTRAZENECA AB Sweden
  • Boehringer Ingelheim Vetmedica GmbH
  • Novo Nordisk A/S
  • Universität des Saarlandes (Saarland University) (UdS)
  • University of Zagreb School of Medicine (UZM)
  • Fakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica (FDRH BB)
  • Innovation Acta S.r.l. (INN-ACTA)
  • Echosens
  • Gilead Sciences Ireland UC (Gilead)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.